Literature DB >> 26365139

GABAergic Modulation in Diabetic Encephalopathy-Related Depression.

Carlos Alberto Yasin Wayhs1, Helena Maria Tannhauser Barros, Carmen Regla Vargas.   

Abstract

Central nervous system is not spared from the deleterious effects of diabetes, since several studies have described neuropsychological and neurobehavioral changes in diabetic subjects, suggesting that diabetic encephalopathy should be recognized as a complication of this complex metabolic disorder. In fact, psychiatric manifestations may accompany this encephalopathy, since the prevalence of depression in diabetic patients is much higher than in the general population. Furthermore, evidences from preclinical and clinical studies suggest that GABA plays a role both in the pathophysiology of the diabetic encephalopathy-related depression. So, this review addresses the GABAergic modulation in diabetic encephalopathy-related depression. Data presented from literature support the association between GABA and depressive- like behaviors in diabetic encephalopathy, being this neurotransmitter a potential target for the treatment of diabetes, depression and related comorbidities.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26365139     DOI: 10.2174/1381612821666150914121331

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  4 in total

1.  The antidepressant-like activity of AC-5216, a ligand for 18KDa translocator protein (TSPO), in an animal model of diabetes mellitus.

Authors:  Zhi-Kun Qiu; Jia-Li He; Xu Liu; Guan-Hua Zhang; Jia Zeng; Hong Nie; Yong-Gang Shen; Ji-Sheng Chen
Journal:  Sci Rep       Date:  2016-11-25       Impact factor: 4.379

2.  Notoginsenoside R1 ameliorates diabetic encephalopathy by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation.

Authors:  Yadong Zhai; Xiangbao Meng; Yun Luo; Yongmei Wu; Tianyuan Ye; Ping Zhou; Shilan Ding; Min Wang; Senbao Lu; Lili Zhu; Guibo Sun; Xiaobo Sun
Journal:  Oncotarget       Date:  2018-01-16

Review 3.  Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis.

Authors:  Ping Zhou; Weijie Xie; Shuaibing He; Yifan Sun; Xiangbao Meng; Guibo Sun; Xiaobo Sun
Journal:  Cells       Date:  2019-02-28       Impact factor: 6.600

Review 4.  Catalpol in Diabetes and its Complications: A Review of Pharmacology, Pharmacokinetics, and Safety.

Authors:  Ying Bai; Ruyuan Zhu; Yimiao Tian; Rui Li; Beibei Chen; Hao Zhang; Bingke Xia; Dandan Zhao; Fangfang Mo; Dongwei Zhang; Sihua Gao
Journal:  Molecules       Date:  2019-09-11       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.